SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

NewAmsterdam Pharma doses first participant in Phase 2b SPINOZA trial

NewAmsterdam Pharma dosed the first participant in its Phase 2b SPINOZA trial evaluating obicetrapib in preclinical Alzheimer’s disease.

NAMSW

Related stories